🎉 Congratulations to today's "Daily Best" winners!
Each receives 50 USDT for their outstanding in-depth articles! 👏
📝 Today's winners & articles
@Mr_qiang777 https://www.gate.com/post/status/19028534
@Coinstages https://www.gate.com/zh/post/status/19031206
@PlayerYU https://www.gate.com/zh/post/status/19038966
🔥 The event is heating up — 3 winners are selected daily!
You could be tomorrow's pick! Share your market insights now and win 50 USDT plus official exposure!
👉 Join now: gate.com/post
#GateSquare #DeepCreationCamp #DailyBest
Madrigal Pharmaceuticals Signs Global siRNA Licensing Deal With Ribo
Madrigal Pharmaceuticals Inc. has announced a global licensing agreement with Suzhou Ribo Life Science Co. Ltd. to develop six preclinical small interfering RNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). The deal includes an upfront payment of $60 million to Ribo, with potential milestone payments up to $4.4 billion plus royalties. This agreement expands Madrigal’s pipeline beyond its approved MASH therapy, Rezdiffra, aiming to provide genetically targeted treatment approaches for the liver disease.